Biparatopic binding of ISB 1442 to CD38 in trans enables increased cell antibody density and increased avidity
ISB 1442 is a bispecific biparatopic antibody in clinical development to treat hematological malignancies. It consists of two adjacent anti-CD38 arms targeting non-overlapping epitopes that preferentially drive binding to tumor cells and a low-affinity anti-CD47 arm to enable avidity-induced blockin...
Saved in:
| Main Authors: | Jeremy Loyau, Thierry Monney, Marco Montefiori, Fedir Bokhovchuk, Jeremy Streuli, Matthew Blackburn, Arnaud Goepfert, Lydia N. Caro, Samitabh Chakraborti, Stefania De Angelis, Camille Grandclément, Stanislas Blein, M. Lamine Mbow, Ankita Srivastava, Mario Perro, Stefano Sammicheli, Eugene A. Zhukovsky, Michael R. Dyson, Cyrille Dreyfus |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Taylor & Francis Group
2025-12-01
|
| Series: | mAbs |
| Subjects: | |
| Online Access: | https://www.tandfonline.com/doi/10.1080/19420862.2025.2457471 |
| Tags: |
Add Tag
No Tags, Be the first to tag this record!
|
Similar Items
-
Engineering hydrophobicity and manufacturability for optimized biparatopic antibody–drug conjugates targeting c-MET
by: Andreas Evers, et al.
Published: (2024-12-01) -
Leveraging HER2-targeted biparatopic antibodies in solid tumors
by: Xinlin Liu, et al.
Published: (2025-04-01) -
Biparatopic antibodies: therapeutic applications and prospects
by: David L. Niquille, et al.
Published: (2024-12-01) -
Building a potent TREM2 agonistic, biparatopic, common light chain antibody
by: Ana da Silva Almeida, et al.
Published: (2025-12-01) -
ADA/CD26 axis increases intra-tumor PD-1+CD28+CD8+ T-cell fitness and affects NSCLC prognosis and response to ICB
by: Ornella Franzese, et al.
Published: (2024-12-01)